Related Experiment Video

Updated: May 31, 2026

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

Immunobiology of transplantation: impact on targets for large and small molecules

A M Azimzadeh1, J R Lees, Y Ding

  • 1Department of Surgery, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Clinical Pharmacology and Therapeutics
|July 1, 2011
PubMed

Insights

Organ transplantation faces challenges from immunosuppressive drugs causing side effects and chronic rejection. New biologic therapies targeting immune pathways offer hope for improved graft survival and reduced complications.

Area of Science:

  • Immunology
  • Transplantation Medicine
  • Drug Development

Background:

  • Organ transplantation is a vital treatment for end-stage organ failure.
  • Current immunosuppressive drugs have significant side effects, including infection, malignancy, and cardiovascular issues.
  • These drugs are often ineffective against chronic rejection, leading to late graft loss.

Purpose of the Study:

  • To review the fundamental mechanisms of solid-organ allograft rejection.
  • To identify novel therapeutic targets for preventing organ transplant rejection.
  • To discuss recent clinical trial results and emerging therapies in transplantation.

Main Methods:

  • Literature review of fundamental concepts in allograft rejection.
  • Analysis of current immunosuppressive drug limitations.
  • Exploration of new therapeutic strategies, including biologics.
  • Discussion of recent clinical trial data and novel therapies.

Main Results:

  • Standard immunosuppression carries risks of infection, malignancy, and metabolic disorders.
  • Chronic rejection remains a major cause of long-term graft failure.
  • Targeting innate and adaptive immunity pathways presents promising therapeutic avenues.
  • Emerging biologics and therapies show potential for improved outcomes.

Conclusions:

  • Advancements in organ transplantation require novel therapeutic approaches beyond current immunosuppression.
  • Future strategies will likely involve biologics targeting specific immune pathways to combat rejection.
  • Continued research into new therapies is crucial for enhancing long-term graft survival and patient well-being.

More Related Videos

Murine Full-thickness Skin Transplantation07:59

Murine Full-thickness Skin Transplantation

Published on: January 2, 2017

Investigating the Immunological Mechanisms Underlying Organ Transplant Rejection05:10

Investigating the Immunological Mechanisms Underlying Organ Transplant Rejection

Published on: August 20, 2007

Related Concept Videos

Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview
Tissue Transplantation01:24

Tissue Transplantation

Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...